Istradefylline for the treatment of Parkinson's disease

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.1, 2012-01, pp. : 111-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite

Istradefylline effective adjunct therapy for Parkinson's disease

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

By Perez-Lloret Santiago Merello Marcelo

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1097-1107

Informa Healthcare

Access to resources Recommend Favorite

Safinamide in the treatment of Parkinson's disease

By Schapira Anthony HV

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2261-2268

Informa Healthcare

Access to resources Recommend Favorite